COIOSDeep risk insights through multi-disciplinary research across the globe
people walking on a street
Item confirms Peer-reviewed Added

GLP-1/GIP agonist BGM0504 reduced weight by up to 18% at 24 weeks

In 120 Chinese adults with overweight or obesity and no diabetes, weekly BGM0504 reduced weight by 10.7% to 18.3% at 24 weeks, as compared to no change on placebo.

A phase 2 trial randomised 120 Chinese adults with overweight or obesity and no diabetes to BGM0504 at three doses or placebo for 24 weeks. Mean weight fell by 10.7% on the 5 mg dose and by 18.3% on the 15 mg dose. Adverse events were most commonly gastrointestinal, drug-related events rose with dose from 53% to 93%, and none led to withdrawal.

Why it is interesting: Dose-ranging evidence for a further dual GLP-1/GIP agonist, against placebo rather than an existing drug.

Source
Diabetes, Obesity and Metabolism, 17 September 2026
Paper
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Authors
Ji L, Yang G, Huang Y, Ding H, Xie D, Jiang X et al.
DOI
10.1111/dom.71193
Type
Peer-reviewed article
Design
Phase 2 randomised double-blind placebo-controlled trial, n=120, 24 weeks, four arms
Verdict
Confirms prior evidence
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today